Does low HDL cholesterol with low large HDL suggest impaired HDL maturation and reduced reverse cholesterol transport?

A metabolic phenotype characterized by low total high-density lipoprotein cholesterol (HDL-C) paired with low concentrations of large HDL particles points to distinct functional and structural abnormalities in lipid metabolism.

Mechanistic drivers of HDL remodeling

• The maturation of HDL relies on highly coordinated enzymatic pathways. Lecithin-cholesterol acyltransferase (LCAT) is the primary driver of this process, esterifying free cholesterol on nascent, small discoidal pre-β HDL to convert them into spherical, cholesteryl ester-rich mature HDL.
• Phospholipid transfer protein (PLTP) facilitates the fusion of smaller particles to generate larger HDL subclasses. Conversely, cholesteryl ester transfer protein (CETP) remodels and shrinks large HDL particles by exchanging cholesteryl esters for triglycerides with apoB-containing lipoproteins.
• A reduction in LCAT activity blocks the progressive enlargement of HDL3 to larger HDL2 or mature α-HDL subfractions. This shifts the particle distribution away from large, mature spherical HDL toward a predominance of small, immature, discoidal pre-β particles, manifesting clinically as low total HDL-C and low large HDL.

Impact on reverse cholesterol transport

• Cholesterol efflux capacity (CEC) is the initial, rate-limiting step of reverse cholesterol transport (RCT), which removes excess cholesterol from peripheral macrophage foam cells.
• Large, mature HDL particles act as essential acceptors for ABCG1- and SR-BI-mediated cholesterol efflux.
• Impaired HDL maturation directly limits the availability of these functional, large mature HDL subclasses. This deficit reduces overall CEC, thereby compromising the entire RCT pathway's capacity to transport cholesterol back to the liver.

Bottom line

• Concurrently low levels of total HDL-C and large HDL particles indicate impaired HDL maturation kinetics and reduced reverse cholesterol transport capacity, primarily driven by disruptions in key enzymatic remodeling pathways such as LCAT.